GLUE
NASDAQ · Biotechnology
Monte Rosa Therapeutics Inc
$20.70
-0.01 (-0.05%)
Open$20.78
Previous Close$20.71
Day High$21.54
Day Low$20.63
52W High$25.77
52W Low$4.12
Volume—
Avg Volume1.24M
Market Cap1.55B
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+85.7% upside
Current
$20.70
$20.70
Target
$38.45
$38.45
$28.40
$38.45 avg
$50.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 125.76M | 401.98M | 400.93M |
| Net Income | -39,282,930 | -29,192,444 | -34,329,564 |
| Profit Margin | -31.2% | -7.3% | -8.6% |
| EBITDA | -46,632,640 | -51,685,540 | -47,809,490 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 |
| Rev Growth | — | +22.8% | -9.2% |
| Debt/Equity | — | 0.43 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |